Loading clinical trials...

A Study Of Heart Disease Using AI-Enabled Electrocardiography And Focused Cardiac Ultrasound | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

A Study Of Heart Disease Using AI-Enabled Electrocardiography And Focused Cardiac Ultrasound

Screening for Heart Disease Using AI-Enabled Electrocardiography and Focused Cardiac Ultrasound: the AI CVD Screen Study.

NCT07351656•Mayo Clinic

View on ClinicalTrials.gov

Summary

A study to evaluate feasibility, diagnostic yield, accuracy, and actionable thresholds of POC, immediate-feedback AI-ECG + AI FoCUS screening for cardiac disease in well described community populations.

Eligibility

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adolescents and young adults:
•Enrollment in a high-school, college or a resident in MN during the study period
•Age 15-29 years
•Informed consent (and assent for minors)
•Adult patients (\>30 years of age, with pre-specified subgroups 30-64 and 65+))
•Adult female aged 18 to 49 years
•Pregnant at the time of enrollment
•Receiving obstetric care at identified study site(s)
•Willing and able to provide informed consent

Exclusion Criteria

•Presence of a pacemaker or defibrillator
•Inability to obtain a quality ECG tracing
•Community dwelling adults:
•Inability to provide informed consent to participate in the study
•Pregnant women:
•Inability to provide consent

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

February 1, 2026

Primary Completion Date

February 1, 2028

Completion Date

February 1, 2028

Last Updated

January 20, 2026

Enrollment

19,300

ESTIMATED participants

Conditions

Heart Disease

Interventions

Focused Cardiac Ultrasound

DIAGNOSTIC_TEST

6-Lead AI-ECG

DIAGNOSTIC_TEST

12-Lead AI-ECG

DIAGNOSTIC_TEST

Contacts

Amanda Priebe

CONTACT

507-422-6932 Priebe.Amanda@mayo.edu

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

NCT06690151

Heart Disease CongenitalNeurodevelopmental Disorder

View study

RECRUITINGPHASE1

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

NCT05647213

Univentricular HeartCongenital Heart Disease+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Of Heart Disease Using AI-Enabled Electrocardiography And Focused Cardiac Ultrasound

Inclusion Criteria

Exclusion Criteria

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Prospective Evaluation of AI-ECG for SHD Detection

Lumason® Infusion vs. Bolus Administrations

Pulmonary Hypertension in Left Heart Disease